We assess therapeutic assets and platforms to help investors and life sciences teams understand the evidence, development risks, and scientific differentiation.
Is the target linked to the disease?
Does the intervention act as claimed?
What has this approach demonstrated?
Is clinical benefit demonstrated?
Example evidence gapEvidence gaps can occur at any stage. We examine where the interpretation depends on untested assumptions.
See an assessment in practice01 SERVICES
Three ways to investigate an opportunity or resolve a scientific question.
Assess a therapeutic asset or platform: the biological rationale, study quality, translational gaps, and material scientific risks.
Compare mechanisms, competing assets, and published evidence to understand an opportunity’s scientific differentiation.
Answer a specific scientific question through focused evidence review and technical analysis, including structural and computational methods where they add value.
02 APPROACH
Each assessment connects the scientific question to the supporting data, their limitations, and the implications for your decision.
Agree on the decision, research boundaries, and the written output you need.
Review primary literature, relevant regulatory records, and company disclosures.
Evaluate methods, controls, alternative explanations, and translational relevance.
Deliver a referenced brief with findings, material uncertainties, and follow-up questions.
03 INSIGHTS
A sample assessment of the evidence behind a therapeutic opportunity.
ILLUSTRATIVE ASSESSMENT
A genetic observation can support a therapeutic target. Evaluating a particular intervention requires a different kind of evidence.
Selected historical studies, 2006–2017.
A demonstration of the method, separate from client work.
| Claim | Evidence | Assessment |
|---|---|---|
| Human genetics supports PCSK9 as a therapeutic target. | Loss-of-function variants associated with lower LDL cholesterol and fewer coronary events.Cohen et al. · NEJM, 2006 | Supports the target |
| Evolocumab reduces cardiovascular events. | FOURIER evaluated evolocumab against placebo on a background of statin therapy.Sabatine et al. · NEJM, 2017 | Supports this intervention |
| A new PCSK9 agent will show the same benefit. | The studies above do not establish this. The new candidate requires its own supporting evidence. | Gap to resolve |
04 ABOUT HYULEON
Hyuleon Strategies is an independent research and advisory firm focused on scientific due diligence in life sciences. We combine scientific and regulatory research, data analysis, and competitive intelligence to assess therapeutic opportunities.
Anna leads Hyuleon’s scientific due diligence and research engagements, drawing on more than 20 years of experience in biomedical research, data analysis, and research leadership. Her background connects molecular and computational science with human physiology and disease biology. She brings these perspectives together to assess therapeutic rationale, examine the strength of supporting evidence, and identify scientific risks relevant to investment and development decisions.
Hovhannes brings experience in applied AI, machine learning, and quantitative finance, including causal inference, model development, and the evaluation of AI systems. He advises Hyuleon on data quality, analytical assumptions, and the limits of what results can support.
05 CONTACT
Tell us about the opportunity or scientific question, the output you need, and your timing.
A high-level introduction is enough to begin.
For other questions, email us.